Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue
Trial Parameters
Brief Summary
The objective of the study is to establish the safety profile of the autologous engineered osteochondral tissues (eOCT) in treating traumatic chondral lesions in patients.
Eligibility Criteria
Inclusion Criteria: * Age: Subjects who are in the age range of 18-60 years * Location: Single symptomatic cartilage defect on medial or lateral femoral condyle * Size \& Containment: Contained single focal cartilage lesion of size \~1-4 cm square * Grading: Cartilage damage ICRS/Outerbridge grade III/IV reaching subchondral bone (As diagnosed by MRI) * Conservative treatments failed (for \> 4 months) Exclusion Criteria: Disease Factor--- * Previous cartilage repair surgery (OATS or ACI/MACI) in the index knee * Previous injectional treatments such as HA/PRP/stem cell in the index knee within 3 months before informed consent * Presence of a clinically relevant patellofemoral cartilage lesion in the index knee (patella/trochlea/both) * Inflammatory joint disease (specific or non-specific arthritis) * Metabolic diseases (gout or rheumatism) * Advanced Osteoarthritis (Radiologically apparent degenerative joint disease in the target knee as determined by Kellgren \& Lawrence Grade \>2) * O